• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Immunol . Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients

tetano

Editor, Senior Moderator
Eur J Immunol


. 2020 Oct 18.
doi: 10.1002/eji.202048908. Online ahead of print.
Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 patients


Anna E Oja[SUP] 1 [/SUP], Anno Saris[SUP] 2 3 [/SUP], Cherien A Ghandour[SUP] 1 [/SUP], Natasja A M Kragten[SUP] 1 [/SUP], Boris M Hogema[SUP] 4 [/SUP], Esther J Nossent[SUP] 3 5 [/SUP], Leo M A Heunks[SUP] 3 6 [/SUP], Susan Cuvalay[SUP] 7 [/SUP], Ed Slot[SUP] 8 [/SUP], Federica Linty[SUP] 9 [/SUP], Francis H Swaneveld[SUP] 7 [/SUP], Hans Vrielink[SUP] 7 [/SUP], Gestur Vidarsson[SUP] 9 [/SUP], Theo Rispens[SUP] 10 [/SUP], Ellen van der Schoot[SUP] 9 [/SUP], Ren? A W van Lier[SUP] 1 [/SUP], Anja Ten Brinke[SUP] 10 [/SUP], Pleun Hombrink[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. Understanding the immune response that provides specific immunity but may also lead to immunopathology is crucial for the design of potential preventive and therapeutic strategies. Here, we characterized and quantified SARS-CoV-2 specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. Furthermore, in these critically ill patients, a massive influx of circulating T cells into the lungs was observed, overwhelming the local T cell compartment, and indicative of vascular leakage. The observed disparate T and B cell responses could be indicative of a deregulated immune response in critically ill COVID-19 patients. This article is protected by copyright. All rights reserved.

Keywords: CD4+ T cells; COVID-19; IgG; SARS-CoV-2; antibody response.
 
Back
Top Bottom